Antipsychotics and the Risk of Unexpected Death in Children and Youth
抗精神病药物与儿童和青少年意外死亡的风险
基本信息
- 批准号:10540790
- 负责人:
- 金额:$ 63.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdolescentAdultAdverse effectsAge YearsAggressive behaviorAntipsychotic AgentsAnxietyAnxiety DisordersAttention deficit hyperactivity disorderBehavior DisordersBenefits and RisksBipolar DisorderCardiovascular systemCase StudyCentral Nervous System DepressantsCessation of lifeChildChlorpromazineClinicalDataDatabasesDeath CertificatesDepressive disorderDiseaseDoseEvaluationGrowthIncidenceIncidence StudyIndividualInjuryLifeLinkMedicaidMetabolicMinorMood DisordersNeurologic EffectOverdosePatientsPersonsPharmaceutical PreparationsPopulationPredispositionPrevalencePsychosesPublic HealthRecommendationRiskRisk AdjustmentRoleSafetySchizophreniaStructureSuicideSurrogate EndpointTennesseeTestingTherapeuticTherapeutic InterventionTherapeutic UsesYouthalternative treatmentatypical antipsychoticcardiovascular risk factorclinical practicecomorbiditymortalitymortality riskrespiratoryrisk minimization
项目摘要
Each year an estimated 1.3 million persons ≤24 years of age receive 7 million antipsychotic
prescriptions in the U.S. Although the primary indications for antipsychotics are schizophrenia and related
psychoses, with no other treatment alternatives, an estimated 90% of antipsychotic prescriptions for
children and youth are for other, less serious conditions, including attention-deficit/hyperactivity disorder
(ADHD), disruptive or aggressive behaviors, affective disorders including bipolar disorder, and anxiety.
However, other recommended therapeutic interventions for children and youth with these disorders are
thought to have fewer adverse effects.
Antipsychotics, which increase the risk of cardiovascular and all-cause mortality in adults, have serious
adverse cardiovascular, metabolic, respiratory, and neurologic effects in children and adolescents that
plausibly increase the risk of death in this population. We recently found that antipsychotic users of
doses>50mg chlorpromazine equivalents (median starting dose) had a greater than 3-fold increased risk of
unexpected death, leading to a 64% increase in total mortality (HR = 1.64 [1.03-2.63]). In contrast, the
adjusted risk of deaths from injuries or suicides did not increase nor was there increased risk of death from
any cause for lower doses of antipsychotics.
Our data indicate antipsychotics increase risk of unexpected deaths, particularly cardiovascular deaths.
The increased risk is clinically meaningful: the incidence of unexpected death in higher-dose antipsychotic
users equaled that of injuries and suicides, which account for two-thirds of deaths in children and
adolescents. Thus, death should be considered as a potential harm when prescribing antipsychotics for
children and youth. However, to guide clinical practice, data are needed that define antipsychotic-related
mortality: 1) according to antipsychotic indication; and 2) according to important factors that practitioners
can control: a) individual drug, b) dose, and c) concurrent central nervous system (CNS) depressants.
We will address these questions using the national Medicaid Analytical Extract (MAX) database, which
includes more than 15 years of longitudinal data that can be linked to death certificates for the estimated
39% of children in the U.S. who are Medicaid enrollees. There are two specific aims:
Aim 1: Test the hypothesis that the risk of unexpected deaths and total mortality in children and youth who
are antipsychotic new users with a) ADHD or disorders of behavior/conduct, b) unipolar depressive or
anxiety disorders, or c) bipolar disorders is greater than that for comparable patients starting alternative
medications.
Aim 2: Define how risk of unexpected deaths and total mortality in children and youth who are antipsychotic
new users varies with a) individual drug, b) dose, and c) concurrent CNS depressants.
每年估计有130万≤24岁的人接受700万抗精神病药物治疗
虽然抗精神病药物的主要适应症是精神分裂症和相关疾病,
精神病,没有其他治疗选择,估计90%的抗精神病药物处方,
儿童和青少年是为其他不太严重的情况,包括注意力缺陷/多动症
注意缺陷多动障碍(ADHD)、破坏性或攻击性行为、情感障碍(包括双相情感障碍)和焦虑。
然而,对于患有这些疾病的儿童和青少年,
被认为具有较少的不良影响。
抗精神病药物会增加成人心血管疾病和全因死亡的风险,
对儿童和青少年的心血管、代谢、呼吸和神经系统的不良影响,
可能会增加这一人群的死亡风险。我们最近发现服用抗精神病药物的人
剂量> 50 mg氯丙嗪当量(起始剂量中位数)的患者,
意外死亡,导致总死亡率增加64%(HR = 1.64 [1.03-2.63])。而反观
调整后的受伤或自杀死亡风险没有增加,
减少抗精神病药物剂量的原因
我们的数据表明,抗精神病药物增加意外死亡的风险,特别是心血管死亡。
增加的风险具有临床意义:高剂量抗精神病药物中意外死亡的发生率
使用者的死亡率与受伤和自杀的死亡率相当,占儿童死亡人数的三分之二,
青少年。因此,在为患者开具抗精神病药时,应将死亡视为一种潜在危害。
儿童和青年。然而,为了指导临床实践,需要数据来定义抗精神病药物相关的
死亡率:1)根据抗精神病药物适应症; 2)根据从业者认为
可以控制:a)单个药物,B)剂量,和c)并发中枢神经系统(CNS)抑制剂。
我们将使用国家医疗补助分析提取(MAX)数据库来解决这些问题,
包括超过15年的纵向数据,这些数据可以与死亡证明联系起来,
39%的美国儿童是医疗补助计划的参与者。有两个具体目标:
目的1:检验以下假设:
是抗精神病药物新使用者,患有a)ADHD或行为/行为障碍,B)单相抑郁或
焦虑症,或c)双相情感障碍大于可比患者开始替代治疗
药物治疗
目的2:确定儿童和青少年服用抗精神病药物后意外死亡的风险和总死亡率
新使用者随a)个体药物、B)剂量和c)并发CNS抑制剂而变化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WAYNE A RAY其他文献
WAYNE A RAY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WAYNE A RAY', 18)}}的其他基金
Outcomes of non-vitamin K anticoagulants in atrial fibrillation
非维生素 K 抗凝剂治疗心房颤动的结果
- 批准号:
10360648 - 财政年份:2020
- 资助金额:
$ 63.41万 - 项目类别:
Outcomes of non-vitamin K anticoagulants in atrial fibrillation
非维生素 K 抗凝剂治疗心房颤动的结果
- 批准号:
10578795 - 财政年份:2020
- 资助金额:
$ 63.41万 - 项目类别:
Antipsychotics and the Risk of Unexpected Death in Children and Youth
抗精神病药物与儿童和青少年意外死亡的风险
- 批准号:
10084784 - 财政年份:2019
- 资助金额:
$ 63.41万 - 项目类别:
Antipsychotics and the Risk of Unexpected Death in Children and Youth
抗精神病药物与儿童和青少年意外死亡的风险
- 批准号:
10328243 - 财政年份:2019
- 资助金额:
$ 63.41万 - 项目类别:
Preventing Gastroduodenal Bleeding in Oral Anticoagulant Users
预防口服抗凝剂使用者的胃十二指肠出血
- 批准号:
9068218 - 财政年份:2013
- 资助金额:
$ 63.41万 - 项目类别:
Preventing Gastroduodenal Bleeding in Oral Anticoagulant Users
预防口服抗凝剂使用者的胃十二指肠出血
- 批准号:
8666807 - 财政年份:2013
- 资助金额:
$ 63.41万 - 项目类别:
Preventing Gastroduodenal Bleeding in Oral Anticoagulant Users
预防口服抗凝剂使用者的胃十二指肠出血
- 批准号:
8499621 - 财政年份:2013
- 资助金额:
$ 63.41万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 63.41万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 63.41万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 63.41万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 63.41万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 63.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 63.41万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 63.41万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 63.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 63.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 63.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)